BicycleTx Limited

Bicycle has developed a proprietary bicyclic peptide technology that enables the discovery of a new class of drug candidates with antibody-like selectivity and specificity. The company is well financed by a group of top-tier VCs and is applying the technology to drug discovery projects in several therapeutic areas. The company also plans to also enter selected research collaborations to make the platform available to pharma partners.